Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-607P (RNA, U6 small nuclear 607, pseudogene) is a **pseudogene** related to the U6 small nuclear RNA, which itself is a critical component of the spliceosome complex mediating RNA splicing in eukaryotic cells[3]. Pseudogenes of U6 are non-coding genomic elements resembling the U6 snRNA gene sequence but are typically nonfunctional due to genetic alterations accumulated over time[2]. Unlike functional U6 snRNA, which is essential for pre-mRNA splicing, RNU6-607P is not actively transcribed into a functional RNA or protein product and does not participate in canonical molecular pathways. Its presence in the genome reflects evolutionary history and the activity of retrotransposon-mediated genomic rearrangement[2]. While some pseudogenes in other contexts have been implicated in gene regulation via non-coding RNAs[5][7], there is no evidence that RNU6-607P has any such functional or disease-related impact. It is not considered a therapeutic target, receptor, enzyme, or a clinically relevant biomarker.
None (not a therapeutic target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 607, pseudogene (RNU6-607P).